Showing results (161-170 of 203) with videos related to
Sort By:
Pageof 21
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.Contemporary Clinical Trials|November 2, 2020
Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European countryGeert Molenberghs, Marc Buyse, Steven Abrams, et al.BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.Journal of the National Cancer Institute|September 7, 2006
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerMarc Buyse, Sherene Loi, Laura van't Veer, et al.Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.Journal of the National Cancer Institute|February 16, 2006
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisChristos Sotiriou, Pratyaksha Wirapati, Sherene Loi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.European Urology|May 22, 2024
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized TrialsPraful Ravi, Wanling Xie, Marc Buyse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.Pageof 21